Clinical trials
Locally Advanced Colorectal Cancer clinical trials
Below are recruiting locally advanced colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07407504RecruitingPhase 1
GenSci145 for advanced solid tumors with PIK3CA mutation
This trial tests a new oral drug, GenSci145, alone or with other drugs, for people whose advanced cancer has a PIK3CA gene change and has grown after standard treatments. It aims to see if this drug can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT05965531RecruitingPhase 2
TAS-102 plus radiation before surgery for rectal cancer
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
Guangzhou, GuangdongAges 18–70 - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Denver, ColoradoAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07661641RecruitingPhase 1
Study of new radioactive treatments for GRPR-positive tumors
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
Melbourne N., VictoriaAges 18 years+ - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Sacramento, CaliforniaAges 18 years+ - NCT07279077RecruitingPhase 2
Low-dose radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75 - NCT07535112RecruitingPhase 1
Testing BAY 3771249 for Advanced Colorectal Cancer With KRAS Mutation
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT07020247RecruitingPhase 3
Personalized radiation plus chemo with or without immunotherapy for rectal cancer
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
Chengdu, SichuanAges 18 years+ - NCT07230639RecruitingPhase 2
Shorter radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a shorter course of radiation combined with chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT03179540Recruiting
Watch-and-wait treatment after rectal cancer radiation
This trial looks at a “non-surgery” approach for some people with locally advanced rectal cancer who respond very well to radiation plus chemotherapy. If your cancer shows a complete clinical response on follow-up checks, the study may help you avoid an immediate major operation while closely monitoring you.
Toronto, OntarioAges 18 years+ - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Montreal, QuebecAges 18–100 - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06399757RecruitingPhase 1/Phase 2
A study of APL-5125 for advanced solid tumors
This trial tests a new drug called APL-5125 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. If you have certain types of advanced cancer, this study may offer a new option.
Duarte, CaliforniaAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+
Hear when a new Locally Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced colorectal cancer?
- Yes. Clin2 currently lists 283 recruiting locally advanced colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.